Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion.

Algorithm Attenuated mucopolysaccharidosis Delayed puberty Dysostosis multiplex Early diagnosis Enzyme replacement therapy Glycosaminoglycans Growth impairment Joint contractures Lysosomal enzyme deficiency

Journal

European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 29 11 2018
accepted: 23 01 2019
revised: 21 01 2019
pubmed: 12 2 2019
medline: 26 7 2019
entrez: 12 2 2019
Statut: ppublish

Résumé

Growth impairment together with bone and joint involvement is common to most patients with mucopolysaccharidosis (MPS) disorders. The genetic basis for these metabolic disorders involves various enzyme deficiencies responsible for the catabolism of glycosaminoglycans (GAGs). The incomplete degradation and subsequent accumulation of GAGs result in progressive tissue damage throughout the body. Bone ossification is particularly affected, with the consequent onset of dysostosis multiplex which is the underlying cause of short stature. Joint manifestations, whether joint contractures (MPS I, II, VI, VII) or hyperlaxity (MPS IV), affect fine motor skills and quality of life. Subtle decreases in growth velocity can begin as early as 2-4 years of age. Pediatricians are in the front line to recognize or suspect MPS. However, given the rarity of the disorders and variable ages of symptom onset depending on disease severity, recognition and diagnostic delays remain a challenge, especially for the attenuated forms. Prompt diagnosis and treatment can prevent irreversible disease outcomes.Conclusion: We present a diagnostic algorithm based on growth velocity decline and bone and joint involvement designed to help pediatricians recognize early manifestations of attenuated forms of MPS. We illustrate the paper with examples of abnormal growth curves and subtle radiographic nuances. What is Known: • As mucopolysaccharidoses (MPSs) are rare genetic disorders infrequently seen in clinical practice, there can be a lag between symptom onset and diagnosis, especially of attenuated forms of the disease. • This highlights the need for increased disease awareness to recognize early clinical signs and subsequently initiate early treatment to improve outcomes (normal height potential) and possibly prevent or delay the development of irreversible disease manifestations. What is New: • Growth impairment co-presenting with limited range of joint motion and radiographic anomalies in children should raise suspicions of possible attenuated MPS (AMPS). • Experts present a diagnostic algorithm with detailed focus on the decline in growth velocity, delayed puberty and limitation in joint mobility seen in children with AMPS, to shorten time-to-diagnosis and treatment and potentially improve patient outcome.

Identifiants

pubmed: 30740618
doi: 10.1007/s00431-019-03330-x
pii: 10.1007/s00431-019-03330-x
pmc: PMC6438949
doi:

Types de publication

Journal Article

Langues

eng

Pagination

593-603

Références

Br J Hosp Med (Lond). 2011 Feb;72(2):91-5
pubmed: 21378615
Eur J Pediatr. 2008 Mar;167(3):267-77
pubmed: 18038146
J Pediatr. 2004 May;144(5):581-8
pubmed: 15126990
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v41-8
pubmed: 22210670
Acta Paediatr. 2005 Jul;94(7):872-7
pubmed: 16188808
J Pediatr. 2016 Nov;178:219-226.e1
pubmed: 27788836
J Bone Joint Surg Am. 1996 Aug;78(8):1149-55
pubmed: 8753706
Mol Genet Metab. 2014 Feb;111(2):63-72
pubmed: 24388732
Pediatr Rheumatol Online J. 2009 Oct 23;7:18
pubmed: 19852785
J Inherit Metab Dis. 2011 Apr;34(2):489-97
pubmed: 21253827
JIMD Rep. 2015;18:1-11
pubmed: 25518809
Mol Genet Metab. 2012 Nov;107(3):513-20
pubmed: 23022072
J Inherit Metab Dis. 2007 Apr;30(2):165-74
pubmed: 17347914
Eur J Pediatr. 2013 Jul;172(7):965-70
pubmed: 23468122
Pediatrics. 2009 Jan;123(1):229-40
pubmed: 19117887
J Inherit Metab Dis. 2005;28(6):1011-7
pubmed: 16435194
Genet Mol Biol. 2012 Dec;35(4 (suppl)):924-31
pubmed: 23411665
Neuropediatrics. 2016 Oct;47(5):285-92
pubmed: 27308871
Ann Neurol. 2014 Nov;76(5):747-53
pubmed: 25103575
Genet Mol Biol. 2014 Jun;37(2):315-29
pubmed: 25071396
Pediatr Neonatol. 2016 Jun;57(3):181-7
pubmed: 26522251
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v26-33
pubmed: 22210667
Mol Genet Metab. 2013 May;109(1):41-8
pubmed: 23537841
Mol Genet Metab. 2016 Feb;117(2):84-94
pubmed: 26452513
Horm Res. 2003;59(4):180-3
pubmed: 12649571
Mol Genet Metab. 2007 Mar;90(3):329-37
pubmed: 17185020
J Med Genet. 2016 Jun;53(6):403-18
pubmed: 26908836
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v19-25
pubmed: 22210666
Ann Endocrinol (Paris). 2017 Jun;78(2):106-107
pubmed: 28457480
Mol Genet Metab. 2018 May;124(1):1-10
pubmed: 29627275
Mol Genet Metab. 2013 May;109(1):54-61
pubmed: 23452954
Joint Bone Spine. 2017 Dec;84(6):663-670
pubmed: 28196778
Insights Imaging. 2013 Aug;4(4):443-59
pubmed: 23645566
J Pediatr Rehabil Med. 2010;3(1):25-38
pubmed: 20563263
Mol Genet Metab Rep. 2014;1:5-18
pubmed: 24955330
Mol Genet Metab Rep. 2017 Sep 27;13:64-68
pubmed: 28983455
Mol Genet Metab. 2015 Nov;116(3):195-203
pubmed: 26422116
Clin Rheumatol. 2014 May;33(5):725-31
pubmed: 24221504
World J Pediatr. 2015 Aug;11(3):226-31
pubmed: 25410665
Am J Med Genet A. 2008 May 15;146A(10):1286-95
pubmed: 18412124
Orphanet J Rare Dis. 2016 Apr 26;11:50
pubmed: 27112191
Mol Genet Metab. 2007 Feb;90(2):171-80
pubmed: 17011223
J Pediatr. 2009 Jun;154(6):859-64.e3
pubmed: 19217123
Genet Med. 2014 Oct;16(10):759-65
pubmed: 24675674
J Korean Med Sci. 2014 Feb;29(2):254-60
pubmed: 24550654
Biochim Biophys Acta. 2011 Nov;1812(11):1542-56
pubmed: 21827850
Expert Opin Investig Drugs. 2002 May;11(5):675-85
pubmed: 11996648
Mol Genet Metab. 2016 Apr;117(4):438-46
pubmed: 26846156
Mol Genet Metab Rep. 2016 Aug 02;8:67-73
pubmed: 27536552
Acta Paediatr. 2007 Apr;96(455):63-70
pubmed: 17391446
Eur J Pediatr. 2012 Jun;171(6):911-9
pubmed: 22234477
J Inherit Metab Dis. 2012 Nov;35(6):1071-9
pubmed: 22441840
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:406-16
pubmed: 23858624
Acta Paediatr. 2012 Apr;101(4):e183-8
pubmed: 22077147

Auteurs

Nathalie Guffon (N)

Reference center of Inherited Metabolic disorder, CERLYMM, Département de Pédiatrie, HCL Hopital Femme Mère Enfant, 59 Boulevard Pinel, 69677, Bron cedex, France. nathalie.guffon-fouilhoux@chu-lyon.fr.

Pierre Journeau (P)

Paediatric Orthopaedic Surgery Department, Lorraine University Hospital Centre, Children's Hospital, Vandoeuvre lès Nancy, France.

Anaïs Brassier (A)

Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France.

Juliane Leger (J)

Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Pediatric Endocrinology Diabetology Department, Reference Centre for Endocrine Growth and Development Diseases, Paris Diderot University, Sorbonne Paris Cité, F-75019, Paris, France.

Bertrand Chevallier (B)

Groupe de Pédiatrie Générale - Société Française de Pédiatrie, Boulogne-Billancourt, Department of Pediatrics and Pediatric Emergency, Ambroise-Paré Hospital, Boulogne-Billancourt, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH